We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review.
- Authors
Gaudette, Étienne; Rizzardo, Shirin; Wladyka, Sasha B.; Rahman, Tuhin; Pothier, Kevin R.
- Abstract
Because we are not aware of any study that has scrutinized drugs not launched in Canada, we sought to take a first step in assessing these drugs and determining whether their limited access warrants concern. Only 2 of the PMPRB11 countries, Japan and Australia, are not represented in the EMA and, like Canada, have their own drug approval body. An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review Sources: Meds Entry Watch 2016, 2017, 2018, 5th and 6th editions;[6]-[10] Health Canada's Notice of Compliance database; Health Canada's New Drug Submissions Completed website; and Health Canada's New Drug Submissions Under Review website.
- Subjects
CANADA; CANADA. Health Canada; DRUG approval
- Publication
Canadian Medical Association Journal (CMAJ), 2023, Vol 195, Issue 23, pE815
- Publication type
Article
- DOI
10.1503/cmaj.230339